Tag: Drugs
Search News
Study links widely-used drug azathioprine to skin cancers
14th September 2018
A drug used to treat inflammatory bowel disease and arthritis, and prevent organ rejection in transplant patients, has been identified as an important contributor to skin cancer development in a study by researchers from Queen Mary University of London, including our Barts Cancer Research UK Centre (BCC) Bioinformatics team, the University of Dundee and the Wellcome Sanger Institute.
Read more
BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials
15th June 2018
Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.
Read more
International Clinical Trials Day 2018
21st May 2018
International Clinical Trials Day is celebrated on 20th May each year in recognition of the clinical trials conducted around the world, which ensure that research from the laboratory can be translated into patient benefit. The progress that is continuing to be made in cancer research, resulting in cancer survival rates doubling in the last 40 years, would not be possible without the researchers, clinicians, nurses and, of course, patients that are involved in clinical trials each year.
Read more
London Pancreas Workshop 2018
11th May 2018
On Friday 4th May, BCI hosted the seventh London Pancreas Workshop, co-organised by Prof Hemant Kocher and our Director Prof Nick Lemoine, which attracted delegates from across Europe and America, with over 140 attendees in total. The biennial event is recognised as a forum for state-of-the-art clinical and basic research in pancreatic cancer.
Read more
Research reveals how breast cancer drug can accelerate cancer cell growth
1st May 2018
The breast cancer drug lapatinib which is designed to shrink tumours can sometimes cause them to grow in the lab, according to a new study published in eLife. By understanding the molecular basis of this phenomenon, scientists hope that their findings will lead to safer treatment options and drug design in the future.
Read more
Using a modified adenovirus to overcome treatment resistance in prostate cancer
27th April 2018
Researchers from BCI’s Centre for Molecular Oncology, led by Dr Gunnel Halldén, have identified a mechanism by which a modified flu-like virus, called AdDD, is able to negate resistance to a drug called mitoxantrone and increase tumour cell killing in prostate cancer models. This mechanism is dependent on B-cell lymphoma 2 (Bcl-2)- a protein involved in the regulation of cell death (apoptosis).
Read more